Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Full-dose versus half-dose botulinum toxin type A injection in benign essential blepharospasm
TCTR20240320002Phase 1Completed
- Sponsor
- Faculty of Medicine, Thammasat University
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of botulinum toxin type A in idiopathic blepharospasm (BEB) (2 arms), sponsored by Faculty of Medicine, Thammasat University. Primary endpoints: Efficacy comparison between full-dose and half-dose botulinum toxin type A and Complication profile of full-dose versus half-dose botulinum toxin type A. Started Apr 2022; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
idiopathic blepharospasm (BEB)
Beyond the preview
Go deeper on TCTR20240320002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240320002.